TheraPsil MDMA-Assisted Psychotherapy Training Program

TheraPsil announced a new MDMA-Assisted Psychotherapy Training Program as part of its work to expand access to psychedelic-assisted psychotherapy in Canada. The program was described as a response to growing demand for training and treatment in MDMA-assisted psychotherapy for trauma survivors. Curriculum development and rollout were to be led by Dr. Ingrid Pacey, a TheraPsil trainer who served as Principal Investigator of the MAPS Phase 2 MDMA trial in Vancouver. The organization said the pilot phase would launch in early 2024. The training was intended for practitioners who had successfully completed the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program. TheraPsil also noted that the expansion would support access to legal MDMA-assisted psychotherapy through Health Canada’s Special Access Program.